Journal of Computer-Aided Molecular Design

, Volume 25, Issue 3, pp 223–235 | Cite as

Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors

Article

Abstract

A semiempirical quantum mechanical PM6-DH2 method accurately covering the dispersion interaction and H-bonding was used to score fifteen structurally diverse CDK2 inhibitors. The geometries of all the complexes were taken from the X-ray structures and were reoptimised by the PM6-DH2 method in continuum water. The total scoring function was constructed as an estimate of the binding free energy, i.e., as a sum of the interaction enthalpy, interaction entropy and the corrections for the inhibitor desolvation and deformation energies. The applied scoring function contains a clear thermodynamical terms and does not involve any adjustable empirical parameter. The best correlations with the experimental inhibition constants (ln K i) were found for bare interaction enthalpy (r 2 = 0.87) and interaction enthalpy corrected for ligand desolvation and deformation energies (r 2 = 0.77); when the entropic term was considered, however, the correlation becomes worse but still acceptable (r 2 = 0.52). The resulting correlation based on the PM6-DH2 scoring function is better than previously published function based on various docking/scoring, SAR studies or advanced QM/MM approach, however, the robustness is limited by number of available experimental data used in the correlation. Since a very similar correlation between the experimental and theoretical results was found also for a different system of the HIV-1 protease, the suggested scoring function based on the PM6-DH2 method seems to be applicable in drug design, even if diverse protein–ligand complexes have to be ranked.

Keywords

CDK2 Semiempirical quantum mechanical method PM6-DH2 Non-covalent interaction Scoring function Drug design 

Abbreviations

CDK2

Cyclin-dependent kinase 2

MM

Molecular mechanics

QM

Quantum mechanics

SQM

Semiempirical quantum mechanics

PI

Protein (P)–inhibitor (I) complex

Notes

Acknowledgments

This work was a part of research project No. Z40550506 of the Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic and was supported by Grants No. LC512 and MSM6198959216 from the Ministry of Education, Youth and Sports of the Czech Republic. The support of Praemium Academiae, Academy of Sciences of the Czech Republic, awarded to P.H. in 2007, is also acknowledged. It was also supported by The Czech Science Foundation (P208/11/0295). This work was supported by the Operational Program Research and Development for Innovations—European Social Fund (CZ.1.05/2.1.00/03.0058).

Supplementary material

10822_2011_9413_MOESM1_ESM.zip (3.3 mb)
ESM1 (ZIP 3.30 MB)

References

  1. 1.
    Morgan DO (1997) Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261–291CrossRefGoogle Scholar
  2. 2.
    Malumbres M, Barbacid M (2005) Mammalian cyclin-dependent kinases. Trends Biochem Sci 30(11):630–641CrossRefGoogle Scholar
  3. 3.
    Malumbres M, Barbacid M (2009) Cell cycle, cdks and cancer: a changing paradigm. Nat Rev Cancer 9(3):153–166CrossRefGoogle Scholar
  4. 4.
    Child ES, Hendrychova T, McCague K, Futreal A, Otyepka M, Mann DJ (2010) A cancer-derived mutation in the pstaire helix of cyclin-dependent kinase 2 alters the stability of cyclin binding. Biochim Biophys Acta Mol Cell Res 1803(7):858–864CrossRefGoogle Scholar
  5. 5.
    Cohen P (1999) The development and therapeutic potential of protein kinase inhibitors. Curr Opin Chem Biol 3(4):459–465CrossRefGoogle Scholar
  6. 6.
    Besson A, Dowdy SF, Roberts JM (2008) Cdk inhibitors: cell cycle regulators and beyond. Dev Cell 14(2):159–169CrossRefGoogle Scholar
  7. 7.
    Fischer PM, Lane DP (2000) Inhibitors of cyclin-dependent kinases as anticancer therapeutics. Curr Med Chem 7:1213–1245Google Scholar
  8. 8.
    Knockaert M, Greengard P, Meijer L (2002) Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 23(9):417–425CrossRefGoogle Scholar
  9. 9.
    Meijer L, Raymond E (2003) Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 36(6):417–425CrossRefGoogle Scholar
  10. 10.
    Johnson LN (2009) Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys 42(1):1–40CrossRefGoogle Scholar
  11. 11.
    Tetsu O, McCormick F (2003) Proliferation of cancer cells despite cdk2 inhibition. Cancer Cell 3(3):233–245CrossRefGoogle Scholar
  12. 12.
    Murray AW (2004) Revisiting the cell cycle: cyclins revisited. Cell 116:221–234CrossRefGoogle Scholar
  13. 13.
    Echalier A, Endicott JA, Noble MEM (2010) Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochim Biophys Acta Proteins Proteomics 1804(3):511–519CrossRefGoogle Scholar
  14. 14.
    De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH (1997) Inhibition of cyclin-dependent kinases by purine analogues—crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 243(1–2):518–526CrossRefGoogle Scholar
  15. 15.
    De Azevedo WF, Mueller-Dieckman HJ, Schulze-Gahmen U, Worland PJ, Sausville EA, Kim SH (1996) Structural basis for specificity and potency of a flavonoid inhibitor of human cdk2, a cell cycle kinase. Proc Natl Acad Sci USA 93:2735–2740CrossRefGoogle Scholar
  16. 16.
    Ducrot P, Legraverend M, Grierson DS (2000) 3d-qsar comfa on cyclin-dependent kinase inhibitors. J Med Chem 43:4098–4108CrossRefGoogle Scholar
  17. 17.
    Otyepka M, Krystof V, Havlicek L, Siglerova V, Strnad M, Koca J (2000) Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2. J Med Chem 43:2506–2513CrossRefGoogle Scholar
  18. 18.
    Otyepka M, Kriz Z, Koca J (2002) Dynamics and binding modes of free cdk2 and its two complexes with inhibitors studied by computer simulations. J Biomol Struct Dyn 20(2):141–154Google Scholar
  19. 19.
    Vadivelan S, Sinha BN, Irudayam SJ, Jagarlapudi SARP (2007) Virtual screening studies to design potent cdk2-cyclin a inhibitors. J Chem Inf Model 47(4):1526–1535CrossRefGoogle Scholar
  20. 20.
    Halperin I, Ma BY, Wolfson H, Nussinov R (2002) Principles of docking: an overview of search algorithms and a guide to scoring functions. Proteins Struct Funct Genet 47(4):409–443CrossRefGoogle Scholar
  21. 21.
    Brooijmans N, Kuntz ID (2003) Molecular recognition and docking algorithms. Annu Rev Biophys Biomol Struct 32:335–373CrossRefGoogle Scholar
  22. 22.
    Leach AR, Shoichet BK, Peishoff CE (2006) Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J Med Chem 49(20):5851–5855CrossRefGoogle Scholar
  23. 23.
    Zhou T, Huang D, Caflisch A (2008) Is quantum mechanics necessary for predicting binding free energy? J Med Chem 51(14):4280–4288CrossRefGoogle Scholar
  24. 24.
    Raha K, Merz KM (2004) A quantum mechanics-based scoring function: study of zinc ion-mediated ligand binding. J Am Chem Soc 126(4):1020–1021CrossRefGoogle Scholar
  25. 25.
    Lu YX, Shi T, Wang Y, Yang HY, Yan XH, Luo XM, Jiang HL, Zhu WL (2009) Halogen bonding-a novel interaction for rational drug design? J Med Chem 52(9):2854–2862CrossRefGoogle Scholar
  26. 26.
    Riley KE, Jurecka P, Pitonak M, Hobza P (2010) Stabilization and structure calculations for noncovalent interactions in extended molecular systems based on wave function and density functional theories. Chem Rev 110:5023–5063CrossRefGoogle Scholar
  27. 27.
    Dobes P, Otyepka M, Strnad M, Hobza P (2006) Interaction energies for the purine inhibitor roscovitine with cyclin-dependent kinase 2: correlated ab initio quantum-chemical, dft and empirical calculations. Chem Eur J 12(16):4297–4304CrossRefGoogle Scholar
  28. 28.
    Raha K, Peters MB, Wang B, Yu N, Wollacott AM, Westerhoff LM, Merz KM (2007) The role of quantum mechanics in structure-based drug design. Drug Dis Today 12(17–18):725–731CrossRefGoogle Scholar
  29. 29.
    Zhou T, Huang DZ, Caflisch A (2010) Quantum mechanical methods for drug design. Curr Top Med Chem 10(1):33–45CrossRefGoogle Scholar
  30. 30.
    Menikarachchi LC, Gascon JA (2010) Qm/mm approaches in medicinal chemistry research. Curr Top Med Chem 10(1):46–54CrossRefGoogle Scholar
  31. 31.
    Cavalli A, Carloni P, Recanatini M (2006) Target-related applications of first principles quantum chemical methods in drug design. Chem Rev 106(9):3497–3519CrossRefGoogle Scholar
  32. 32.
    Peters MB, Raha K, Merz KM (2006) Quantum mechanics in structure-based drug design. Curr Opin Drug Discovery Dev 9(3):370–379Google Scholar
  33. 33.
    Raha K, Merz KM (2005) Large-scale validation of a quantum mechanics based scoring function: predicting the binding affinity and the binding mode of a diverse set of protein-ligand complexes. J Med Chem 48(14):4558–4575CrossRefGoogle Scholar
  34. 34.
    Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S (2005) A combination of docking, qm/mm methods, and md simulation for binding affinity estimation of metalloprotein ligands. J Med Chem 48(17):5437–5447CrossRefGoogle Scholar
  35. 35.
    Merz KM (2010) Limits of free energy computation for protein-ligand interactions. J Chem Theory Comput 6(5):1769–1776CrossRefGoogle Scholar
  36. 36.
    Wollacott AM, Merz KM (2007) Assessment of semiempirical quantum mechanical methods for the evaluation of protein structures. J Chem Theory Comput 3(4):1609–1619CrossRefGoogle Scholar
  37. 37.
    Stewart JJP (2007) Optimization of parameters for semiempirical methods v: modification of nddo approximations and application to 70 elements. J Mol Model 13(12):1173–1213CrossRefGoogle Scholar
  38. 38.
    Stewart JJP (2009) Application of the pm6 method to modeling proteins. J Mol Model 15(7):765–805CrossRefGoogle Scholar
  39. 39.
    Rezac J, Fanfrlik J, Salahub D, Hobza P (2009) Semiempirical quantum chemical pm6 method augmented by dispersion and h-bonding correction terms reliably describes various types of noncovalent complexes. J Chem Theory Comput 5(7):1749–1760CrossRefGoogle Scholar
  40. 40.
    Korth M, Pitonak M, Rezac J, Hobza P (2010) A transferable h-bonding correction for semiempirical quantum-chemical methods. J Chem Theory Comput 6(1):344–352CrossRefGoogle Scholar
  41. 41.
    Hayik SA, Dunbrack R, Merz KM (2010) Mixed quantum mechanics/molecular mechanics scoring function to predict protein-ligand binding affinity. J Chem Theory Comput 6(10):3079–3091CrossRefGoogle Scholar
  42. 42.
    Fanfrlik J, Bronowska AK, Rezac J, Prenosil O, Konvalinka J, Hobza P (2010) A reliable docking/scoring scheme based on the semiempirical quantum mechanical pm6-dh2 method accurately covering dispersion and h-bonding: Hiv-1 protease with 22 ligands. J Phys Chem B 114:12666–12678CrossRefGoogle Scholar
  43. 43.
    Jurecka P, Cerny J, Hobza P, Salahub DR (2007) Density functional theory augmented with an empirical dispersion term. Interaction energies and geometries of 80 noncovalent complexes compared with ab initio quantum mechanics calculations. J Comput Chem 28(2):555–569CrossRefGoogle Scholar
  44. 44.
    Deng YQ, Roux B (2006) Calculation of standard binding free energies: aromatic molecules in the t4 lysozyme l99a mutant. J Chem Theory Comput 2(5):1255–1273CrossRefGoogle Scholar
  45. 45.
    Deng YQ, Roux B (2009) Computations of standard binding free energies with molecular dynamics simulations. J Phys Chem B 113(8):2234–2246CrossRefGoogle Scholar
  46. 46.
    Wang JY, Deng YQ, Roux B (2006) Absolute binding free energy calculations using molecular dynamics simulations with restraining potentials. Biophys J 91(8):2798–2814CrossRefGoogle Scholar
  47. 47.
    Marenich AV, Cramer CJ, Truhlar DG (2009) Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions. J Phys Chem B 113(18):6378–6396CrossRefGoogle Scholar
  48. 48.
    Chang CEA, Chen W, Gilson MK (2007) Ligand configurational entropy and protein binding. Proc Natl Acad Sci USA 104(5):1534–1539CrossRefGoogle Scholar
  49. 49.
    Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz JKM, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA (1995) A 2nd generation force-field for simulation of proteins, nucleic-acids and organic-molecules. J Am Chem Soc 117:5179–5197CrossRefGoogle Scholar
  50. 50.
    Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, Onufriev A, Simmerling C, Wang B, Woods RJ (2005) The amber biomolecular simulation programs. J Comput Chem 26(16):1668–1688CrossRefGoogle Scholar
  51. 51.
    Duan Y, Wu C, Chowdhury S, Lee MC, Xiong GM, Zhang W, Yang R, Cieplak P, Luo R, Lee T, Caldwell J, Wang JM, Kollman P (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 24(16):1999–2012CrossRefGoogle Scholar
  52. 52.
    Wang JM, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25(9):1157–1174CrossRefGoogle Scholar
  53. 53.
    Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) Ucsf chimera—a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605–1612CrossRefGoogle Scholar
  54. 54.
    Klamt A, Schuurmann G (1993) Cosmo—a new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient. J Chem Soc Perkin Trans 2(5):799–805Google Scholar
  55. 55.
    Jayaram B, Sprous D, Beveridge DL (1998) Solvation free energy of biomacromolecules: parameters for a modified generalized born model consistent with the amber force field. J Phys Chem B 102(47):9571–9576CrossRefGoogle Scholar
  56. 56.
    Frisch MJ (2009) Gaussian 09, revision a.02. Gaussian Inc., WallingfordGoogle Scholar
  57. 57.
    Tomasi J, Mennucci B, Cammi R (2005) Quantum mechanical continuum solvation models. Chem Rev 105(8):2999–3093CrossRefGoogle Scholar
  58. 58.
    Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912–1934CrossRefGoogle Scholar
  59. 59.
    Ewing TJA, Kuntz ID (1997) Critical evaluation of search algorithms for automated molecular docking and database screening. J Comput Chem 18(9):1175–1189CrossRefGoogle Scholar
  60. 60.
    Otyepka M, Bartova I, Kriz Z, Koca J (2006) Different mechanisms of cdk5 and cdk2 activation as revealed by cdk5/p25 and cdk2/cyclin a dynamics. J Biol Chem 281:7271–7281CrossRefGoogle Scholar
  61. 61.
    Ibrahim DA, El-Metwally AM (2010) Design, synthesis, and biological evaluation of novel pyrimidine derivatives as cdk2 inhibitors. Eur J Med Chem 45(3):1158–1166CrossRefGoogle Scholar
  62. 62.
    Duca JS, Madison VS, Voigt JH (2008) Cross-docking of inhibitors into cdk2 structures. 1. J Chem Inf Model 48(3):659–668CrossRefGoogle Scholar
  63. 63.
    Sato H, Shewchuk LM, Tang J (2006) Prediction of multiple binding modes of the cdk2 inhibitors, anilinopyrazoles, using the automated docking programs gold, flexx, and ligandfit: an evaluation of performance. J Chem Inf Model 46(6):2552–2562CrossRefGoogle Scholar
  64. 64.
    Guimaraes CRW, Cardozo M (2008) Mm-gb/sa rescoring of docking poses in structure-based lead optimization. J Chem Inf Model 48(5):958–970CrossRefGoogle Scholar
  65. 65.
    Ferrara P, Curioni A, Vangrevelinghe E, Meyer T, Mordasini T, Andreoni W, Acklin P, Jacoby E (2006) New scoring functions for virtual screening from molecular dynamics simulations with a quantum-refined force-field (qrff-md). Application to cyclin-dependent kinase 2. J Chem Inf Model 46(1):254–263CrossRefGoogle Scholar
  66. 66.
    Pearce BC, Langley DR, Kang J, Huang HW, Kulkarni A (2009) E-novo: an automated workflow for efficient structure-based lead optimization. J Chem Inf Model 49(7):1797–1809CrossRefGoogle Scholar
  67. 67.
    Dessalew N, Singh SK (2008) 3d-qsar comfa and comsia study on benzodipyrazoles as cyclin dependent kinase 2 inhibitors. Med Chem 4(4):313–321CrossRefGoogle Scholar
  68. 68.
    Heady L, Fernandez-Serra M, Mancera RL, Joyce S, Venkitaraman AR, Artacho E, Skylaris CK, Ciacchi LC, Payne MC (2006) Novel structural features of cdk inhibition revealed by an ab initio computational method combined with dynamic simulations. J Med Chem 49(17):5141–5153CrossRefGoogle Scholar
  69. 69.
    Hobza P, Muller-Dethlefs K (2010) Non-covalent interactions. RSC Publishing, CambridgeGoogle Scholar
  70. 70.
    Zgarbova M, Otyepka M, Sponer J, Hobza P, Jurecka P (2010) Large-scale compensation of errors in pairwise-additive empirical force fields: comparison of amber intermolecular terms with rigorous dft-sapt calculations. Phys Chem Chem Phys 12:9611–9614CrossRefGoogle Scholar
  71. 71.
    Alzate-Morales JH, Caballero J, Jague AV, Nilo FDG (2009) Insights into the structural basis of n2 and o6 substituted guanine derivatives as cyclin-dependent kinase 2 (cdk2) inhibitors: prediction of the binding modes and potency of the inhibitors by docking and oniom calculations. J Chem Inf Model 49(4):886–899CrossRefGoogle Scholar
  72. 72.
    Zhou T, Caflisch A (2010) High-throughput virtual screening using quantum mechanical probes: discovery of selective kinase inhibitors. Chem Med Chem 5(7):1007–1014Google Scholar
  73. 73.
    Lawrie AM, Noble MEM, Tunnah P, Brown NR, Johnson LN, Endicott JA (1997) Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with cdk2. Nat Struct Biol 4:796–801CrossRefGoogle Scholar
  74. 74.
    Zhao B, Bower MJ, McDevitt PJ, Zhao HZ, Davis ST, Johanson KO, Green SM, Concha NO, Zhou BBS (2002) Structural basis for chk1 inhibition by ucn-01. J Biol Chem 277(48):46609–46615CrossRefGoogle Scholar
  75. 75.
    Arris CE, Boyle TF, Calvert AH, Curtin NJ, Endicott JA, Garman EF, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury P, Johnson LN, Lawrie AM, Newell DR, Noble MEM, Sausville EA, Schultz R, Yu W (2000) Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J Med Chem 43:2797–2804CrossRefGoogle Scholar
  76. 76.
    Wu SY, McNae I, Kontopidis G, McClue SJ, McInnes C, Stewart KJ, Wang SD, Zheleva DI, Marriage H, Lane DP, Taylor P, Fischer PM, Walkinshaw MD (2003) Discovery of a novel family of cdk inhibitors with the program lidaeus: structural basis for ligand-induced disordering of the activation loop. Structure 11(4):399–410CrossRefGoogle Scholar
  77. 77.
    Wang SD, Meades C, Wood G, Osnowski A, Anderson S, Yuill R, Thomas M, Mezna M, Jackson W, Midgley C, Griffiths G, Fleming I, Green S, McNae I, Wu SY, McInnes C, Zheleva D, Walkinshaw MD, Fischer PM (2004) 2-anilino-4-(thiazol-5-yl)pyrimidine cdk inhibitors: synthesis, sar analysis, x-ray crystallography, and biological activity. J Med Chem 47(7):1662–1675CrossRefGoogle Scholar
  78. 78.
    Chu XJ, DePinto W, Bartkovitz D, So SS, Vu BT, Packman K, Lukacs C, Ding QJ, Jiang N, Wang K, Goelzer P, Yin XF, Smith MA, Higgins BX, Chen YS, Xiang Q, Moliterni J, Kaplan G, Graves B, Lovey A, Fotouhi N (2006) Discovery of [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl](2, 3-difluoro-6-methoxyphenyl)methanone (r547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. J Med Chem 49(22):6549–6560CrossRefGoogle Scholar
  79. 79.
    Davies TG, Bentley J, Arris CE, Boyle TF, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Hardcastle IR, Jewsbury P, Johnson LN, Mesguiche V, Newell DR, Noble MEM, Tucker JA, Wang L, Whitfield HJ (2002) Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat Struct Biol 9(10):745–749CrossRefGoogle Scholar
  80. 80.
    Sayle KL, Bentley J, Boyle FT, Calvert AH, Cheng YZ, Curtin NJ, Endicott JA, Golding BT, Hardcastle IR, Jewsbury P, Mesguiche V, Newell DR, Noble MEM, Parsons RJ, Pratt DJ, Wang LZ, Griffin RJ (2003) Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. Bioorg Med Chem Lett 13(18):3079–3082CrossRefGoogle Scholar
  81. 81.
    Meijer L, Bisagni E, Legraverend M (1998) Purine derivatives having, in particular, antiproliferative properties, and their biological uses USA PatentGoogle Scholar
  82. 82.
    Schulze-Gahmen U, Brandsen J, Jones HD, Morgan D, Meijer L, Veselý J, Kim S-H (1995) Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with atp and two inhibitors, olomoucine and isopenthenyladenine. Proteins Struct Funct Genet 22:378–391CrossRefGoogle Scholar
  83. 83.
    Veselý J, Havlíček L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato J-Y, Detivaud L, Leclerc S, Meijer L (1994) Inhibition of cyclin dependent kinases by purine analogues. Eur J Biochem 224:771–786CrossRefGoogle Scholar
  84. 84.
    McIntyre NA, McInnes C, Griffiths G, Barnett AL, Kontopidis G, Slawin AMZ, Jackson W, Thomas M, Zheleva DI, Wang SD, Blake DG, Westwood NJ, Fischer PM (2010) Design, synthesis, and evaluation of 2-methyl- and 2-amino-n-aryl-4, 5-dihydrothiazolo[4, 5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors. J Med Chem 53(5):2136–2145CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.Regional Centre of Advanced Technologies and Materials, Department of Physical Chemistry, Faculty of SciencePalacký UniversityOlomoucCzech Republic
  2. 2.Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic and Center for Biomolecules and Complex Molecular SystemsPrague 6Czech Republic
  3. 3.Center of Molecular Biology and Gene Therapy, Department of Internal Medicine–HematooncologyUniversity Hospital BrnoBrnoCzech Republic

Personalised recommendations